THE BELGIAN OPHTHALMIC ASSOCIATIONS
View abstract
Cet abstract a été assigné à session Poster session in O'Bistro
| Titre | Therapeutic potential of placental growth factor (PlGF) inhibition in scar formation after glaucoma filtration surgery |
| But | We checked the hypothesis that placental growth factor (PlGF) may be a target for improvement of the outcome of glaucoma filtration surgery (GFS). |
| Méthodes | The effect of the anti-murine PlGF-antibody (5D11D4) was investigated in a mouse model of GFS. Immediately after surgery 5D11D4 (5.2µg) or 1C8, an irrelevant mouse IgG antibody (4.8 µl), was injected in the anterior chamber (n=10 eyes for both groups). An anti-murine VEGF-R2 antibody (DC101) was used as a positive control (6.2 µg; n=10). Mice were killed on post-operative day 8. Treatment outcome was studied by clinical investigation of the bleb and by immunohistological stainings. All antibodies were kindly provided by ThromboGenics NV. |
| Résultats | Treatment using the anti-PlGF antibody significantly improved surgical outcome by increasing bleb survival and bleb area with 29% compared to negative control (1C8). Postoperative inflammation and angiogenesis was reduced during the first days after surgery and collagen deposition was decreased at later stages. A single administration of anti-VEGF-R2 also significantly improved bleb area with 7% as compared to 1C8, but had no effect on bleb survival. Inhibition of VEGF-R2 only reduced angiogenesis and collagen deposition, but did not influence inflammation. |
| Conclusion | Targeting PlGF with an inhibitory monoclonal antibody is efficacious in improving GFS outcome, possibly even more effectively than inhibition of VEGF-R2, due to its additional effect on inflammation. These results render PlGF an appealing target for ocular wound healing and point to the potential therapeutic benefits of PlGF-inhibition. |
Auteur 1
| Nom | VAN BERGEN |
| Initiales | T |
| Institut | KUL |
| Ville | Leuven |
Auteur 2
| Nom | Jonckx |
| Initiales | B |
| Institut | ThromboGenics |
| Ville | Heverlee |
Auteur 3
| Nom | Hollanders |
| Initiales | K |
| Institut | KUL |
| Ville | Leuven |
Auteur 4
| Nom | Sijnave |
| Initiales | D |
| Institut | KUL |
| Ville | Leuven |
Auteur 5
| Nom | Van de Velde |
| Initiales | S |
| Institut | KUL |
| Ville | Leuven |
Auteur 6
| Nom | Vandewalle |
| Initiales | E |
| Institut | KUL |
| Ville | Leuven |
Auteur 7
| Nom | Moons |
| Initiales | L |
| Institut | KUL |
| Ville | Leuven |
Auteur 8
| Nom | Stassen |
| Initiales | JM |
| Institut | ThromboGenics |
| Ville | Heverlee |
Auteur 9
| Nom | Stalmans |
| Initiales | I |
| Institut | KUL |
| Ville | Leuven |